Similar articles for PMID: 29777005

Year	Number of Results
1995	1
1998	1
1999	1
2000	1
2001	3
2002	1
2003	1
2004	3
2005	2
2006	4
2007	2
2008	1
2009	3
2010	3
2011	4
2012	6
2013	8
2014	10
2015	8
2016	9
2017	16
2018	18
2019	12
2020	11
2021	8
2022	2
2023	2
2024	0

1

Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with ¹³¹I-MIBG.

Kane A, Thorpe MP, Morse MA, Howard BA, Oldan JD, Zhu J, Wong TZ, Petry NA, Reiman R Jr, Borges-Neto S. Kane A, et al. J Nucl Med. 2018 Nov;59(11):1708-1713. doi: 10.2967/jnumed.117.202150. Epub 2018 May 18. J Nucl Med. 2018. PMID: 29777005 Free article.

2

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.

Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A. Ezziddin S, et al. J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16. J Nucl Med. 2014. PMID: 24434296 Free article.

3

Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.

Mulholland N, Chakravartty R, Devlin L, Kalogianni E, Corcoran B, Vivian G. Mulholland N, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):2002-12. doi: 10.1007/s00259-015-3116-4. Epub 2015 Jul 5. Eur J Nucl Med Mol Imaging. 2015. PMID: 26142730

4

Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.

Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Thapa P, et al. Nucl Med Commun. 2016 Oct;37(10):1030-7. doi: 10.1097/MNM.0000000000000547. Nucl Med Commun. 2016. PMID: 27243215

5

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Carlsen EA, et al. Endocr Relat Cancer. 2019 Feb 1;26(2):227-239. doi: 10.1530/ERC-18-0424. Endocr Relat Cancer. 2019. PMID: 30540557 Free article.

6

Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.

Kwekkeboom DJ, Krenning EP. Kwekkeboom DJ, et al. Hematol Oncol Clin North Am. 2016 Feb;30(1):179-91. doi: 10.1016/j.hoc.2015.09.009. Hematol Oncol Clin North Am. 2016. PMID: 26614376 Review.

7

Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.

Limouris GS, Karfis I, Chatzioannou A, Paphiti MI, Lyra M, Gennatas K, Nikou G, Voros D, Pragulidis GP, Polydorou AA, Gouliamos A. Limouris GS, et al. Q J Nucl Med Mol Imaging. 2012 Dec;56(6):551-8. Q J Nucl Med Mol Imaging. 2012. PMID: 23358409 Clinical Trial.

8

Overview and Current Status of Peptide Receptor Radionuclide Therapy.

Bushnell DL, Bodeker KL. Bushnell DL, et al. Surg Oncol Clin N Am. 2020 Apr;29(2):317-326. doi: 10.1016/j.soc.2019.11.005. Surg Oncol Clin N Am. 2020. PMID: 32151363 Review.

9

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB. Mukherjee JJ, et al. Clin Endocrinol (Oxf). 2001 Jul;55(1):47-60. doi: 10.1046/j.1365-2265.2001.01309.x. Clin Endocrinol (Oxf). 2001. PMID: 11453952

10

Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.

Kalshetty A, Ramaswamy A, Ostwal V, Basu S. Kalshetty A, et al. Nucl Med Commun. 2018 Dec;39(12):1143-1149. doi: 10.1097/MNM.0000000000000926. Nucl Med Commun. 2018. PMID: 30308585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year